{"id":205,"date":"2024-11-08T09:50:11","date_gmt":"2024-11-08T09:50:11","guid":{"rendered":"https:\/\/admit:8890\/?page_id=205"},"modified":"2025-05-10T09:37:00","modified_gmt":"2025-05-10T09:37:00","slug":"noticias","status":"publish","type":"page","link":"https:\/\/admit-therapeutics.com\/es\/noticias\/","title":{"rendered":"Noticias"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">Noticias<\/h1>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"wp-block-query is-layout-flow wp-block-query-is-layout-flow\"><ul class=\"columns-3 wp-block-post-template is-layout-grid wp-container-core-post-template-is-layout-50eac3a5 wp-block-post-template-is-layout-grid\"><li class=\"wp-block-post post-1540 post type-post status-publish format-standard hentry category-sin-categorizar-es\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-presenta-el-test-map-ad-en-el-del-xiii-congreso-argentino-de-la-calidad-en-el-laboratorio-clinico-calilab-2026\/\" target=\"_self\" >ADmit Therapeutics presenta el test MAP-AD en el del XIII Congreso Argentino de la Calidad en el Laboratorio Cl\u00ednico (CALILAB 2026)<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 4 de Noviembre de 2026. ADmit Therapeutics participar\u00e1 en la Jornadas de Neurogen\u00e9tica organizadas por MANLAB en el marco del XIII Congreso Argentino de la Calidad en el Laboratorio Cl\u00ednico (CALILAB 2026). La Dra. Carla Trapero presentar\u00e1 el test MAP-AD, el \u00fanico test de pron\u00f3stico en sangre aprobado regulatoriamente (IVDR &#8211; EU 2017\/746) que&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-presenta-el-test-map-ad-en-el-del-xiii-congreso-argentino-de-la-calidad-en-el-laboratorio-clinico-calilab-2026\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1528 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/medicina-de-precision-pionera-para-el-alzheimer-viacare-y-admit-therapeutics-se-alian-para-transformar-la-atencion-neurologica-centrada-en-el-paciente\/\" target=\"_self\" >Medicina de precisi\u00f3n pionera para el Alzheimer: ViaCare y ADmit Therapeutics se al\u00edan para transformar la atenci\u00f3n neurol\u00f3gica centrada en el paciente<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 21 de Octubre de 2026. Ante la enfermedad de Alzheimer, una patolog\u00eda que afecta profundamente no solo a las personas que la padecen, sino tambi\u00e9n a sus familias y seres queridos, la claridad temprana y una orientaci\u00f3n personal, compasiva y cercana resultan fundamentales.\u00a0ViaCare, centro m\u00e9dico privado integral de referencia en Madrid perteneciente al\u00a0Grupo Viamed&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/medicina-de-precision-pionera-para-el-alzheimer-viacare-y-admit-therapeutics-se-alian-para-transformar-la-atencion-neurologica-centrada-en-el-paciente\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1485 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-cierra-un-acuerdo-estrategico-con-hvd-life-sciences-para-acelerar-su-expansion-comercial\/\" target=\"_self\" >ADmit Therapeutics cierra un acuerdo estrat\u00e9gico con HVD Life Sciences para acelerar su expansi\u00f3n comercial<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 15 de Septiembre de 2026. ADmit Therapeutics, una empresa de biotecnolog\u00eda especializada en soluciones diagn\u00f3sticas innovadoras para enfermedades neurodegenerativas, se complace en anunciar una nueva colaboraci\u00f3n con\u00a0HVD Life Sciences, un l\u00edder reconocido en la comercializaci\u00f3n de soluciones de diagn\u00f3stico\u00a0in vitro\u00a0en mercados internacionales. Este acuerdo representa un hito clave en la estrategia de expansi\u00f3n comercial&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-cierra-un-acuerdo-estrategico-con-hvd-life-sciences-para-acelerar-su-expansion-comercial\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1408 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-obtiene-la-certificacion-clia-abriendo-las-puertas-al-mercado-sanitario-de-ee-uu\/\" target=\"_self\" >ADmit Therapeutics Obtiene la Certificaci\u00f3n CLIA, Abriendo las Puertas al Mercado Sanitario de EE.UU.<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 5 de Diciembre de 2025. ADmit Therapeutics ha anunciado hoy la obtenci\u00f3n del\u00a0Certificado CLIA (Clinical Laboratory Improvement Amendments). Esta acreditaci\u00f3n, otorgada por los Centros de Servicios de Medicare y Medicaid (CMS) de EE. UU., avala el cumplimiento de los m\u00e1s\u00a0rigurosos est\u00e1ndares de calidad y fiabilidad\u00a0anal\u00edtica. \u00abEsta certificaci\u00f3n no es solo un sello de calidad;&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-obtiene-la-certificacion-clia-abriendo-las-puertas-al-mercado-sanitario-de-ee-uu\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1392 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-presenta-innovacion-en-sevilla-el-test-map-ad-y-nuevos-datos-de-prediccion-del-alzheimer\/\" target=\"_self\" >ADmit Therapeutics Presenta Innovaci\u00f3n en Sevilla: El Test MAP-AD\u00ae\u00a0y Nuevos Datos de Predicci\u00f3n de la demencia por enfermedad Alzheimer<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 14 de Noviembre, 2025&nbsp;\u2013 ADmit Therapeutics, empresa l\u00edder en diagn\u00f3stico de enfermedades neurodegenerativas, ha confirmado su participaci\u00f3n en la pr\u00f3xima&nbsp;Reuni\u00f3n Anual de la Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN), que se celebrar\u00e1 en Sevilla. La compa\u00f1\u00eda aprovechar\u00e1 el evento para exponer los \u00faltimos desarrollos en la predicci\u00f3n y pron\u00f3stico de la Enfermedad de Alzheimer. El&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-presenta-innovacion-en-sevilla-el-test-map-ad-y-nuevos-datos-de-prediccion-del-alzheimer\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><li class=\"wp-block-post post-1379 post type-post status-publish format-standard hentry category-sin-categorizar\">\n\n<div class=\"wp-block-group\" style=\"padding-top:30px;padding-right:30px;padding-bottom:30px;padding-left:30px\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 style=\"font-size:1.2rem\" class=\"wp-block-post-title\"><a href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-exhibira-su-innovacion-europea-en-medica-2025\/\" target=\"_self\" >ADmit Therapeutics exhibir\u00e1 su innovaci\u00f3n europea en MEDICA 2025<\/a><\/h2>\n\n<div class=\"wp-block-post-excerpt\"><p class=\"wp-block-post-excerpt__excerpt\">Barcelona, 13 de noviembre. Estamos&nbsp;orgullosos&nbsp;de anunciar que nuestra empresa ha sido seleccionada para participar en&nbsp;MEDICA 2025, que tendr\u00e1 lugar del&nbsp;17 al 20 de noviembre de 2025&nbsp;en D\u00fcsseldorf, Alemania. ADmit Therapeutics estar\u00e1 en el Pabell\u00f3n del EIC en Messe D\u00fcsseldorf,&nbsp;Pabell\u00f3n 15, Stand 15B41. Nuestra empresa es una de las&nbsp;15 start-ups&nbsp;respaldadas por el Consejo Europeo de Innovaci\u00f3n&hellip;<\/p><p class=\"wp-block-post-excerpt__more-text\"><a class=\"wp-block-post-excerpt__more-link\" href=\"https:\/\/admit-therapeutics.com\/es\/admit-therapeutics-exhibira-su-innovacion-europea-en-medica-2025\/\">Leer m\u00e1s<\/a><\/p><\/div><\/div><\/div>\n\n<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Noticias<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-205","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=205"}],"version-history":[{"count":18,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/205\/revisions"}],"predecessor-version":[{"id":1006,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/205\/revisions\/1006"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}